As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume. We ranked hese in terms of percentages with the largest increase in short interest first.
STOCK (Ticker) JUNE07 MAY07 Change
GlaxoSmithkline (GSK) 7.74M 4.15M +86%
Boston Scientific (BSX) 32.07M 24.06M +33.3%
Wyeth (WYE) 3.3M 10.37M +28.3%
Labcorp (LH) 4.11M 3.21M +28%
Bristol-Myers (BMY) 26.95M 23.85M +13%
Schering-Plough (SGP) 16.79M 15.27M +9.9%
Medtronic (MDT) 16.11M 15.19M +6%
Pfizer (PFE) 54.48M 52.12M +4.5%
Quest Diagnost. (DGX) 18.00M 17.54M +2.6%
Merck (MRK) 22.82M 22.55M +1.2%
Eli Lilly (LLY) 13.77M 14.07M -2.1%
J&J (JNJ) 15.37M 16.16M -4.9%
Zimmer Holdings (ZMH) 3.89M 4.13M -5.8%
St. Jude MEdical (STJ) 6.53M 7.13M -8.4%
Genentech (DNA) 6.87M 8.16M -15.9%
Abbott Labs (ABT) 11.74M 16.39M -28.3%
Jon C. Ogg
June 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.